ReviewInternational journal of molecular sciences2021
Cachexia as Evidence of the Mechanisms of Resistance and Tolerance during the Evolution of Cancer Disease.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 48 citations in OpenAlex.
- Benefits of an anti-inflammatory diet compared to a low-residue diet during concurrent chemoradiation therapy for patients with locally advanced cervical cancer: a randomized clinical trial.Frontiers in nutrition · 2026Trial
- Trial
- The Clinical Role of Systemic Inflammation-Based Biomarkers in Predicting Mortality in Post-Pneumonectomy Bronchopleural Fistula: A Multicenter Retrospective Analysis.Diagnostics (Basel, Switzerland) · 2025Article
- Age, cancer, and the dual burden of cancer and doxorubicin in skeletal muscle wasting in female rats: which one to blame?Biogerontology · 2025Article
- Cost-Effectiveness of Oral Nutritional Supplements in Malnourished or at Risk of Disease-Related Malnutrition Cancer Patients in North Macedonia.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Article
- Salivary Interleukin-13 and Transforming Growth Factor Beta as Potential Biomarkers of Cancer Cachexia.Cancers · 2024Article
- Metabolomics analysis reveals novel serum metabolite alterations in cancer cachexia.Frontiers in oncology · 2024Article
- Advancing non-small cell lung cancer treatment: the power of combination immunotherapies.Frontiers in immunology · 2024Review
- Emerging markers of cancer cachexia and their relationship to sarcopenia.Journal of cancer research and clinical oncology · 2023Article
- The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review.Translational lung cancer research · 2023Review
- The effects of chemotherapy on resting energy expenditure, body composition, and cancer-related fatigue in women with breast cancer: a prospective cohort study.Cancer & metabolism · 2023Article
- Review
- Cancer cachexia and chronic inflammation: an unbreakable bond.British journal of cancer · 2023Article
- Molecular Basis and Advances in Targeted Immunotherapy for Cancer.International journal of molecular sciences · 2023Article
- What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP's prognostic ability in different cancer types.Oncotarget · 2023Review
- Article
- Review
- Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy.Frontiers in oncology · 2023Article
- The impact of inflammation and acute phase activation in cancer cachexia.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During its evolution, cancer induces changes in patients' energy metabolism that strongly affect the overall clinical state and are responsible for cancer-related cachexia syndrome. To better understand the mechanisms underlying cachexia and its metabolic derangements, research efforts should focus on the events that are driven by the immune system activation during the evolution of neoplastic disease and on the phenomena of "resistance" and "tolerance" typically involved in the human body response against stress, pathogens, or cancer. Indeed, in the case where resistance is not able to eliminate the cancer, tolerance mechanisms can utilize the symptoms of cachexia (anemia, anorexia, and fatigue) to counteract unregulated cancer growth. These notions are also sustained by the evidence that cancer cachexia may be reversible if the resistance and tolerance phases are supported by appropriate antineoplastic treatments. Accordingly, there is no doubt that anticachectic therapies have an irreplaceable role in cases of reversible cancer cachexia where, if harmoniously associated with effective antineoplastic therapies, they can contribute to preserve the quality of life and improve prognosis. Such anticachectic treatments should be based on targeting the complex immunological, inflammatory, and metabolic pathways involved in the complex pathogenesis of cachexia. Meanwhile, the role of the anticachectic therapies is very different in the stage of irreversible cachexia when the available antineoplastic treatments are not able to control the disease and the resistance mechanisms fail with the prevalence of the tolerance phenomena. At this stage, they can be useful only to improve the quality of life, allowing the patient and their family to get a better awareness of the final phases of life, thereby opening to the best spiritual remodulation of the final event, death.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.